摘要
鼻咽癌是中国常见的恶性肿瘤之一,其发病位置隐蔽且在早期临床不容易发现,发现时大多数已经是中晚期。微小核糖核酸(miRNA)是一段长约为22个核苷酸的内源性非编码单链RNA分子。miRNA可以靶向调控多种肿瘤相关基因的表达。随着国内外对miRNA深入研究,肿瘤特异性miRNA成为治疗鼻咽癌的新靶点和预测预后的生物标志物。本文主要从分子生物学特性来综述miRNA在鼻咽癌发生、发展、诊治和预后评估、放疗耐药中的研究现状。
Nasopharyngeal carcinoma is one of the common malignant tumors in China.Its incidence location is hidden and it is not easy to find in the early clinical stage,most of them are already in the middle and late stage when found out.MicroRNA(miRNA)is an endogenous,non-coding single-stranded RNA molecule about 22 nucleotides long.MiRNA can target the expression of a variety of tumor-related genes.With the in-depth research on miRNA at home and abroad,tumor-specific miRNA has become a new target for the treatment of nasopharyngeal carcinoma and a biomarker for prognosis prediction.In this review,the role of miRNA in the pathogenesis,development,diagnosis,treatment,prognosis prediction,and radiotherapy resistance of nasopharyngeal carcinoma was reviewed.
作者
李诗华
周慧
姚俊
Li Shihua;Zhou Hui;Yao Jun(Department of Otolaryngology,Head and Neck Surgery,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,China)
出处
《国际医药卫生导报》
2022年第8期1168-1171,共4页
International Medicine and Health Guidance News
关键词
鼻咽癌
MIRNA
综述
Nasopharyngeal carcinoma
MiRNA
Review
